Form 4: Gilead Sciences Increases Stake in Xilio Therapeutics with Recent Stock and Warrant Acquisitions

Gilead Sciences, a major shareholder in Xilio Therapeutics, has increased its beneficial ownership through the acquisition of common stock and prefunded warrants.

Summary

• On December 18, 2024, Gilead Sciences acquired 1,759,978 shares of Xilio Therapeutics common stock at a price of $1.04 per share.
• Additionally, Gilead Sciences acquired 6,092,816 prefunded warrants with an exercise price of $0.0001, each warrant entitling them to purchase one share of common stock at $1.0399.
• Following these transactions, Gilead Sciences' direct ownership in Xilio Therapeutics increased to 9,105,451 shares of common stock and 9,975,266 prefunded warrants.
• The prefunded warrants are immediately exercisable and have no expiration date, but exercise is limited to ensure Gilead Sciences and its affiliates do not exceed 19.99% ownership of Xilio's outstanding common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports transactions without expressing positive or negative views on the company's prospects. The increased stake could be seen as a positive signal, but it's not explicitly stated.

Positives

• Gilead Sciences' increased investment in Xilio Therapeutics signals confidence in the company's prospects.
• The acquisition of prefunded warrants provides Gilead Sciences with the potential to further increase its stake in Xilio Therapeutics.

Risks

• The exercise of prefunded warrants is subject to a 19.99% ownership limit, which may restrict Gilead Sciences' ability to fully exercise its warrants.
• The document does not provide information on the overall financial health or future prospects of Xilio Therapeutics, so the investment may still carry inherent risks.

Future Outlook

The document does not contain specific forward-looking statements regarding Xilio Therapeutics' future performance or Gilead Sciences' intentions beyond the reported transactions.

Industry Context

Form 4 filings are standard disclosures for significant changes in ownership by company insiders or major shareholders. Gilead's increased stake in Xilio could indicate a strategic interest in Xilio's therapeutic programs or technologies.

Comparison to Industry Standards

• Form 4 filings are a common occurrence in the biopharmaceutical industry, reflecting ongoing investment and ownership adjustments.
• Gilead Sciences is a large cap company, so this investment is not material to them.
• The size of the investment is not significant compared to other investments in the sector.

Stakeholder Impact

• Shareholders of Xilio Therapeutics may view Gilead Sciences' increased investment positively.
• The increased investment may improve employee morale.

Key Dates